AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
PRESS RELEASE AB SCIENCE ANNOUNCES A NEW PUBLICATION ON BIORXIV THAT IDENTIFIES…
Indivumed and University of Rochester Medical Center expand collaboration for patient-centric discovery of novel therapeutics
Two leading entities in cancer research pledge scientific collaboration to advance precision…
Latest Data of InnoCares Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH)
December 08, 2025 21:04 ET Â | Source: InnoCare Pharma BEIJING, Dec. 08,…
ASH 2025 | Updated Data for Ascentage Pharmas Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment
76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI…
Cerevance Showcases Positive Phase 2 Results Demonstrating Significant Reduction in OFF Time with Solengepras as an Adjunctive Treatment in Parkinsons Disease
December 05, 2025 21:00 ET Â | Source: Cerevance, Inc. Phase 2 results…
American Society of Clinical Oncology (ASCO) announces dates for 2026 ASCO Breakthrough and begins accepting submissions for novel oncology research
Global oncology society calls for abstract submissions for research that is shaping…
Rakovina Therapeutics Showcases Compelling Preclinical Data on AI-Discovered CNS-Penetrant ATR/mTOR Inhibitors at the 2025 Society for Neuro-Oncology Annual Meeting
VANCOUVER, British Columbia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc.…
KX-826: Redefining Confidence with Visible Hair Revival
HongKong, Nov. 21, 2025 (GLOBE NEWSWIRE) -- For millions struggling with thinning…
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and…
Belite Bio Announces UKs Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant
November 02, 2025 09:00 ET Â | Source: Belite Bio, Inc MHRA response…